BY Meagan Raeke

Several MD Anderson-led studies at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting focus on using immunotherapy to provide new treatment options for rare, aggressive cancers, including anaplastic thyroid cancer (ATC), glioblastoma, leptomeningeal disease (LMD) and soft-tissue sarcomas. For most of these rare diseases, survival is poor and few – if any – effective treatment options are currently available.


cancer graphic

BY Laura Sussman

Rafael Pantoja had all but lost hope.

The thyroid cancer he had battled for 14 years was back and spreading.

Then, earlier this...

BY Laura Sussman

In a pivotal Phase III study led by researchers at MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic...